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Abstract: Melatonin modulates a wide range of physiological functions with pleiotropic 
effects on the immune system. Despite the large number of reports implicating melatonin 
as an immunomodulatory compound, it still remains unclear how melatonin regulates 
immunity. While some authors argue that melatonin is an immunostimulant, many studies 
have also described anti-inflammatory properties. The data reviewed in this paper  
support the idea of melatonin as an immune buffer, acting as a stimulant under basal or 
immunosuppressive conditions or as an anti-inflammatory compound in the presence of 
exacerbated immune responses, such as acute inflammation. The clinical relevance of the 
multiple functions of melatonin under different immune conditions, such as infection, 
autoimmunity, vaccination and immunosenescence, is also reviewed. 
Keywords: melatonin; pineal; immune system; cytokines; inflammation; infection; 
autoimmunity; vaccination; immunosenescence 
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1. Introduction 
As early as 1926, Berman reported improved resistance to infectious diseases in kittens fed for  
two years with pineal gland extracts from young bulls. Thus, the pineal-immunity relationship was 
already established prior to the discovery of melatonin in 1958 by Aaron Lerner et al. [1], who were 
attempting to isolate the pineal factor responsible for skin lightening in amphibians, which had been 
previously described by McCord and Allen in 1917. In recent decades, skepticism and perplexity 
regarding the relationship between melatonin and the pineal gland has been transformed by numerous 
and rigorous scientific analyses; now, this relationship has not only acquired scientific respectability, 
but is also of great physiological interest. 
Melatonin (N-acetyl-5-methoxy-tryptamine) is an indoleamine that appeared very early during 
evolution. It is present in bacteria, unicellular eukaryotic organisms, invertebrates and vertebrates, algae, 
plants and fungi, and is also found in various edibles, such as vegetables, fruits, herbs and seeds [2]. 
Melatonin is converted from the amino acid tryptophan in two steps: first, from tryptophan into 
serotonin followed by acetylation via arylalkylamine N-acetyltransferase (EC 2.3.1.87; AA-NAT), and 
second, conversion to melatonin by hydroxyindole-O-methyl transferase (EC 2.1.1.4; HIOMT) [3]. 
The exclusive melatonin biosynthetic pathway reflects the high conservation of the molecule 
throughout many phylogenies. The production and release of melatonin from the pineal gland follows 
a circadian rhythm with a peak at night and the lowest levels during the light phase [4]. This temporal 
chemical signal is involved in the synchronization of several rhythmic physiological functions and is 
thus the subject of considerable clinical interest in terms of biological processes related to period and 
phase shifts, such as sleep disturbances, jetlag and shiftwork [5]. In addition to its chronobiotic 
function, melatonin exerts cyto-protective actions by regulating oxidative stress, apoptosis and 
mitochondrial homeostasis [6]. Furthermore, its oncostatic [7] and immunomodulatory activities [8], 
among many others, highlight the potential clinical relevance of melatonin. 
The molecular mechanisms responsible for the pleiotropic effects of melatonin involve two main 
actions: binding to high-affinity G-protein-coupled receptors at the membrane level; and/or interaction 
with intracellular targets to modulate signal transduction pathways, redox-modulated processes, or the 
scavenging of free radicals [9]. 
Since the description of antibodies highly specific to melatonin in the mid-1970s [10], a substantial 
body of research has identified extrapineal sources of melatonin in a number of organs, tissues and 
cells, redefining the classic line of thought that melatonin is an exclusively pineal compound. Over the 
last 20 years, the gastrointestinal tract has been confirmed as an important source of melatonin [11], 
along with skin [12], retina and the Harderian gland [13]. Original studies from the last few decades 
have also identified de novo synthesis of melatonin by the immune system, which was reviewed in [14]. 
The immune system operates through a complex network of coordinated interactions involving 
numerous cells, proteins and molecules to protect the host against foreign agents that enter the body. 
The immune response is the result of two main types of immunity: the innate or non-specific response, 
and the acquired or specific response. The first includes defense mechanisms that are present even 
before infection occurs, facilitating a quick response. These mechanisms respond to microorganisms in 
the same way and with the same intensity, even with repeated infections. Innate immunity only 
involves the identification of specific structures shared by related groups of microorganisms, and it is 
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unable to distinguish between subtle differences for substances that are recognized. The major cellular 
components of the innate response are macrophages, neutrophils, basophils, eosinophils and natural 
killer cells (NK), in addition to various soluble factors, such as the cytokines tumor necrosis  
factor-alpha (TNF-α), interleukin (IL)-1β, IL-6 and IL-8. In contrast to the innate response, the specific 
immune response is quite refined, and the magnitude of the response increases with successive 
exposures to a specific microorganism. T and B lymphocytes are the main components of the acquired 
immune response, in addition to circulating proteins such as antibodies and cytokines. Specific 
immunity consists of humoral and cellular immunity. The first is primarily mediated by antibodies, 
which recognize and bind to extracellular pathogens or non-self molecules, turning them into targets 
for destruction by macrophages, among other functions. Cellular immunity acts on intracellular 
microorganisms and is primarily mediated by cytotoxic T lymphocytes (CD8+), which recognize and 
destroy infected cells, and T helper lymphocytes (Th; CD4+), which are key elements in the regulation 
and coordination of the innate, humoral and cellular responses through the production of a large 
variety of cytokines. Based on the cytokine milieu, the expression of specific transcription factors and 
patterns of protein secretion, Th cells can differentiate primarily into four major phenotypes: Th1, Th2, 
Th17 (effector phenotype), and regulatory T (Treg) cells, which control excessive responses of the 
effector lineages. Th1 cells play a key role in the development of inflammatory processes through the 
production of cytokines such as IFN-γ. Th2 cells produce cytokines such as IL-4, IL-5, IL-10 and  
IL-13 and contribute to the regulation of the humoral and anti-inflammatory responses. Th17 cells, a 
novel subset of CD4+ T cells, have mainly been identified on the basis of RORγt transcription factor 
expression and the production of IL-17 [15]. In addition to their involvement in autoimmunity, Th17 
cells eliminate extracellular pathogens, and their relevance in inflammatory processes is becoming 
increasingly apparent. Currently, Th1/Th17 responses are considered pro-inflammatory, while the Th2 
response is considered anti-inflammatory. The description of Treg cells and their remarkable functions 
in the control of effector cells has also updated the field of immunology. These cells represent a unique 
subpopulation of CD4+ cells (mostly CD25+) for which the expression of the transcription factor 
Foxp3 is a hallmark [16].  
2. Pineal-Immune System Cross-Talk: From the Pineal Gland to the Immune System and Return 
A large body of evidence has shown a clear relationship between the neuroendocrine and immune 
systems. This link is illustrated by a bidirectional communication circuit in which the endogenous 
substances of the neuroendocrine system act on the immune system and vice versa. This network  
also shares a common language via compounds synthesized in both systems, such as acetylcholine, 
adrenocorticotropic hormone (ACTH), endorphin, vasoactive intestinal peptide (VIP), somatostatin 
and growth hormones [17]. 
The pineal gland and its main product, melatonin, are considered members of this network. A 
functional connection between this gland and the immune system has been widely described through 
two main experimental approaches: pinealectomy and rhythmic synchronization between melatonin 
synthesis and the immune system. Pineal ablation promotes massive weight loss in primary and 
secondary lymphoid organs and a decrease in the cellular components and functions associated with 
the innate and specific responses. Furthermore, synchronization between the rhythmicity of melatonin 
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production and circadian and seasonal adjustments in the immune system has been widely reported; 
this is extensively reviewed in [14,18]. 
The pineal gland is also an immune target. Interferon-gamma (IFN-γ) was shown to increase the 
production of melatonin from in vitro-cultured rat pineal glands [19]. Administration of recombinant 
IL-1β inhibited serum melatonin levels in rats through a receptor-mediated mechanism [20], whereas 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) stimulated the synthesis of melatonin both in vivo and in vitro [21]. A study of surgically 
bursectomized chickens revealed the pivotal role of the bursa of Fabricius in the ontogeny of circadian 
melatonin synthesis, as a significant reduction in plasma melatonin levels and NAT activity was 
recorded after bursa of Fabricius ablation [22]. Immunization with sheep red blood cells (SRBCs) also 
caused changes in night NAT activity in chickens [23], whereas peritonitis promoted a downregulation 
of Aa-nat transcription and a subsequent decrease in nocturnal melatonin levels [24]. Recently, a series 
of elegant papers from the Markus group has outlined the hypothesis that mounting inflammatory 
responses involves the suppression of nocturnal melatonin production, reinforcing the idea of 
bidirectional pineal-immune system cross-talk. The transcription of Aa-nat together with the synthesis 
of the melatonin precursor N-acetylserotonin was transiently inhibited by administration of TNF-α to 
in vitro-cultured rat pineal glands [25]. Moreover, suppression of increased nocturnal melatonin in 
mothers with mastitis was highly correlated with increased TNF-α production [26]. Likewise, an 
increase in TNF-α levels after Caesarean section resulted in the suppression of serum melatonin 
nocturnal levels [27]. Additionally, lipopolysaccharide (LPS) treatment not only reduced the 
production of nocturnal melatonin in rats but also enhanced endothelial cell adherence, which was 
normalized after melatonin administration [28]. LPS was shown to induce TNF-α production in the rat 
pineal gland through activating toll-like receptor 4 (TLR-4) [29]. Subsequently, the production of 
TNF-α by pineal gland microglia was found to act on tumor necrosis factor receptor 1 (TNFR1), 
driving the nuclear translocation of NF-κB, which represses Aa-nat transcription and in turn suppresses 
melatonin synthesis [30]. 
A main feature of the neuroendocrine–immune network is the use of a common language. To this 
end, the immune system endogenously produces several peptidic and non-peptidic compounds, such as 
acetylcholine, adrenaline, neurotransmitters and neuroendocrine hormones, which are also typical of 
the neuroendocrine system [31]. A number of studies have suggested possible endogenous melatonin 
synthesis by the immune system. These studies have revealed much evidence for the notion that 
melatonin should not be solely described as a hormone according to the classic definition; this was 
reviewed in [32]. One such piece of evidence that melatonin can be distinguished from a classical 
hormone is that the direct presence of melatonin or key enzymes involved in its synthesis have been 
identified in different non-endocrine organs, such as retina, lens, Harderian gland, gut cells [11,33], 
skin [12] and many others [34,35]. 
Thus, evidence is emerging that the immune system is one source of extrapineal melatonin. At the 
end of the 1980s, the works of Finocchiaro suggested that human peripheral blood mononuclear cells 
(PBMCs) possessed the capacity to produce melatonin in vitro after being cultured in the presence of 
IFN-γ or serotonin [36,37]. In early 2000, two studies revealed the presence of high concentrations of 
melatonin in rat, mouse and human bone marrow [38,39]. Tan et al. described the presence of NAT 
and HIOMT activities in bone marrow cells and noted that significantly higher concentrations of 
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melatonin were still present in rat bone marrow after pinealectomy, indicating de novo synthesis. 
Similar results were described by Conti et al. with human bone marrow cells and in different mouse 
strains. High concentrations of melatonin in long-term bone marrow cultures (four weeks) also 
suggested the endogenous synthesis of melatonin. Rat peritoneal macrophages also produce melatonin 
in vitro after incubation with tryptophan [40]. In addition to the aforementioned sources, melatonin 
and/or its biosynthetic machinery have been located in a variety of immune tissues, organs and cells, 
such as rat, mouse and human thymus [41,42]; spleen, bone marrow and circulating leukocytes [43]; 
mast cells, natural killer cells and eosinophils [34]; and in several immune cell lines [36,39,44,45]. 
Table 1. Distribution and role of melatonin receptors in the immune system. BALT: 
bronchus-associated lymphoid tissue; IL: interleukin; IP3: inositol triphosphate; PBMCs: 
peripheral blood mononuclear cells. Empty spaces indicate unknown function.  
 Receptor Distribution Effector mechanism References 
M
em
br
an
e 
re
ce
pt
or
s 
MT1 
Human PBMCs 
Regulation of IL-2 production 
Regulation of cAMP levels  
[46–48] 
Different subsets of human T 
lymphocytes, B cells and 
monocytes  
 
[46] 
Jurkat (human T cells)  
Regulation of IL-2 production and IL-2R (CD25) levels  
Regulation of cAMP levels  
[44,48–52] 
U937 (human monocyte cells)   [50] 
Mouse thymus   [53] 
Mouse spleen   [53] 
Mouse peritoneal macrophages Regulation of cAMP levels  [51] 
Rat thymus   [54] 
Rat spleen   [54] 
Rat B cells   [54] 
Rat CD4+, CD8+ and CD4+ CD8+ 
thymocytes  
 
[54] 
RBL-2H3 (rat mast cells)   [45] 
Spleen of palm squirrel 
Regulation of organ weight  
Regulation of splenocyte proliferation  
[55–59] 
Thymus of palm squirrel 
Regulation of thymocyte proliferation  
Regulation of IL-2 production 
[55,57,59] 
PBMCs of palm squirrel  [59] 
BALT of quail   
MT2 
Jurkat   [44] 
Mouse thymus  [53] 
Mouse splenocytes Increased proliferation [60] 
Rat thymus   [61] 
Rat spleen   [61] 
Rat leukocytes Inhibition of leukocyte rolling [62] 
RBL-2H3   [45] 
Chicken spleen  
Regulation of splenocyte proliferation  
Regulation of cAMP and IP3 levels  
[41] 
Chicken thymus   [63] 
Chicken lymphocytes   [63] 
BALT of quail  [64] 
Spleen of quail  [65] 
MT1/MT2 Human PBMCs 
Inhibition of TNFα-induced apoptosis  
Activation of ERK signaling pathway  
[66] 
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Table 1. Cont. 
 Receptor Distribution Effector mechanism References 
N
uc
le
ar
 r
ec
ep
to
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RZRα 
Human PBMCs, including different 
subsets of T lymphocytes, B cells 
and monocytes  
 
[46,67] 
Jurkat  [49] 
RPMI 1788 and P16 (human B 
cells)  
Repression of 5-LOX expression 
[68] 
HL-60 (promyelocytes)   [68] 
Mono Mac 6 (monocytes)   [68] 
RORα 
Human PBMCs   [48] 
Human cytotoxic T lymphocytes 
[RORα1]  
 
[46] 
Human PBMCs, including different 
subsets of T lymphocytes, B cells 
and monocytes [RORα2] 
 
[46] 
Jurkat [RORα1, RORα2, RORα3]   [49,50,69] 
U937 [RORα1, RORα2]  Regulation of IL-6 production [50] 
RPMI 1788 and P16 [RORα2, 
RORα3] 
 
[68] 
HL-60 [RORα2, RORα3]   [68] 
Mono Mac 6 [RORα2, RORα3]  [68] 
Mouse thymus and spleen   [53] 
RZR/ROR 
Human PBMCs 
Regulation of IL-2 and IL-6 production and of IL-2R 
(CD25)  
[51,70,71] 
Jurkat Regulation of IL-2 production  [44,49] 
U937 Regulation of IL-6 production  [72] 
An important fact that also supports the relationship between melatonin and the immune system is 
the presence of melatonin receptors in a wide variety of organs and immune cells from various species 
of mammals and birds. Currently, there is enough evidence to affirm that melatonin not only interacts 
with membrane-associated and intracellular targets, but also that this interaction mediates important 
regulatory effects on the immune system (Table 1). 
Despite the relatively high numbers of putative melatonin sources within the immune system, 
knowledge of the physiological actions of local immune-derived melatonin is limited. We were the 
first to report that in vitro-cultured human lymphocytes not only actively synthesize and release 
substantial amounts of melatonin [73], but that this melatonin modulates the IL-2/IL-2 receptor  
(IL-2R) system via receptor-mediated intra-, auto- and/or paracrine actions [51]. The use of luzindole, 
a melatonin membrane receptor antagonist, potentiated the inhibitory effects of PGE2 on IL-2 
production by Jurkat cells, demonstrating the membrane receptor-mediated effects of endogenous 
melatonin [44]. To further investigate the role of immune-derived melatonin in the IL-2/IL-2R system, 
HIOMT and MT1 knock-down Jurkat cells were used. Both low levels of HIOMT activity and MT1 
expression diminished IL-2 production after phytohaemagglutinin (PHA) activation [52]. Colostrum 
immunocompetent cells produced a transient surge of melatonin after in vitro stimulation by 
enteropathogenic Escherichia coli or zymosan, suggesting the involvement of local melatonin in 
modulating the phagocytic capacity of the cells [26]. This is in accordance with the high 
concentrations of melatonin we recorded in PHA-stimulated PBMCs [73]. Additionally, we confirmed 
that high levels of melatonin after optimal PHA stimulation impaired exogenous melatonin action in 
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the production of IL-2, likely via a binding site saturation mechanism [51]. The existence of 
individuals with different immune cell sensitivities to melatonin and the impaired melatonin action 
against an LPS-stimulated inflammatory response observed in human monocytes during winter 
darkness (70 degrees N) [74] also support the notion of a masking effect for endogenously synthesized 
melatonin exerted by the immune system. Similarly, the presence of high amounts of endogenous 
melatonin may be the reason that many authors are able to demonstrate in vitro effects for exogenous 
melatonin only when cells either are not or are only slightly activated [71,75]. Opposing functions for 
NF-κB in the transcriptional control of Aa-nat expression have recently been described in pinealocytes 
versus macrophages, which may represent an interesting switch mechanism in the regulation of pineal 
versus immune-derived melatonin production under inflammatory conditions [76].  
3. Pleiotropic Actions of Melatonin Administration on the Immune Response 
A large amount of evidence has demonstrated the immunomodulatory capacity of melatonin 
administration in both in vivo and in vitro models [14]. Some studies have shown that melatonin 
treatment promotes an increase in the weight of immune organs, both under basal and immunosuppressed 
conditions (Table 2) [77–80]. Conversely, the anti-proliferative effects of melatonin have been 
observed in vitro in PHA-stimulated human lymphocytes [81]. Melatonin also modulates both the 
innate and specific immune responses through regulation of immunocompetent cell proliferation [82,83] 
and secretion of immune mediators, such as cytokines [18]. 
3.1. Immunomodulatory Actions of Melatonin in the Innate Immune Response  
Melatonin modulates the main cellular components of the innate immune response. Multiple daily 
melatonin injections into the pineal glands and surrounding areas in rat brains have been shown to 
promote a significant increase in macrophage/microglia cellularity [84]. NK cells and monocytes were 
also increased in the bone marrow of healthy young mice fed with melatonin [85]. Similarly, the 
administration of melatonin to healthy subjects promoted stimulation of NK cell activity [86], which 
was also enhanced in the spleens and axillary nodes of 24-month-old female rats treated with 
melatonin [87]. Additionally, it has been demonstrated that the chemotaxis index is significantly 
boosted by melatonin. The chemotactic effects that melatonin exerts on leukocytes were revealed with 
healthy human neutrophils and PBMCs in response to in vitro melatonin application [88]. Healthy 
mice receiving 10 consecutive daily intraperitoneal injections showed enhanced antigen presentation 
by splenic macrophages to T cells, which simultaneously occurred with increased MHC class II 
expression and production of IL-1 and TNF-α [89]. Melatonin is also able to enhance the phagocytic 
capacity of heterophils [90]. 
An early hallmark of the inflammatory response is the cascade production of TNF-α, IL-1β and  
IL-6 by activated macrophages. These cytokines are considered to be serum biomarkers of inflammation. 
Splenocytes from healthy mice treated with a very high concentration of melatonin (500 mg/kg) 
produced increased levels of IL-1β, even without in vitro mitogenic stimulation [91]. Experimental 
trauma-hemorrhage in mice gave rise to an immunosuppressed state with low levels of IL-1 and IL-6 
production, which were restored to basal control levels after melatonin treatment [92]. The in vitro 
incubation of human monocytes in the presence of melatonin promoted a pre-activation state, 
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improving the cytotoxic response to LPS [93]. Melatonin also enhanced IL-6 and IL-12 production by 
cultured monocytes, but only under suboptimal stimulation [71,75]. Conversely, melatonin demonstrates 
alternate behavior in situations with exacerbated immune responses. Melatonin reduced neutrophil 
infiltration and levels of inflammatory mediators during rat heatstroke-induced lung inflammation and 
airway hyperreactivity [94,95]. Decreased neutrophil infiltration was also one of the mechanisms by 
which melatonin protected against experimental acute pancreatitis [96]. Melatonin administration upon 
reperfusion decreased the migration of circulatory neutrophils and macrophages/monocytes into 
injured brain and inhibited microglial activation following transient focal cerebral ischemia in  
rats [97]. In addition to chemotaxis, endothelial adherence and permeability is a key process involved 
in the recruitment of immune cells towards targets. Injection of melatonin was found to reduce 
leukotriene B4-induced endothelial cell hyper-adhesiveness, suggesting a reduction in the capacity of 
vascular cells to interact with neutrophils [98]. The endothelial cell barrier-protective effects of 
melatonin have also been described in human umbilical vein endothelial cells with increased permeability 
induced by IL-1β [99]. Melatonin suppressed LPS-induced cyclooxygenase-2 (COX-2) and inducible 
nitric oxide synthase (iNOS) protein levels in the murine macrophage cell line Raw264.7 [100]. A 
microarray analysis of gene expression in LPS-activated Raw cells confirmed the melatonin-induced 
anti-inflammatory profile [101]. Melatonin also downregulated chemokine expression in the  
BV2 murine microglial cell line following LPS stimulation [102]. Melatonin and its derivative  
AFMX suppressed the production of IL-8, a neutrophil chemotactic factor, in human pulmonary 
fibroblasts [103] and LPS-activated peripheral blood neutrophils [104]. A biphasic effect of melatonin 
on the phorbol myristate acid (PMA)-induced respiratory burst in human neutrophils has also been 
described; while low doses (10 nM) increased the response, high doses (2 mM) inhibited it [105]. 
Additionally, melatonin neutralized the exacerbated production of pro-inflammatory mediators, mainly 
cytokines, in a large number of in vivo models of inflammation (Table 3). 
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Table 2. In vivo effects of melatonin under basal and immunosuppressed conditions.  
Immune condition Melatonin effects Melatonin administration References 
Basal 
Increases lymphocyte counts and the blastogenic stimulation ratio of spleen 
and thymus Increases cellularity in thymus and spleen 
25 mg/kg to adult male squirrels for 60 consecutive days during May–June [77] 
Basal Splenic hypertrophy and extramedullary hematopoiesis 25 mg/kg to adult male Syrian hamsters kept under a long photoperiod [78] 
Basal 
Increase in cell numbers of macrophages/microglia and upregulation of MHC 
and CD4 antigens 
Multiple daily injections of melatonin in the pineal gland and different regions 
of 1-day-old rat brains for 7–11 days 
[84] 
Basal Increases bone marrow NK cells and monocytes Daily administration through diet (7–14 days) to young adult male mice [85] 
Basal 
Increases neutrophil chemotactic response to a physiological chemoattractant 
and the expression of intracellular chemokines 
20 mg daily to human volunteers [88] 
Basal Increases in splenocyte proliferation and IL-2 and IL-1β levels 500 mg/kg to young mice [91] 
Aging-induced immunosuppression 
Reverses thymic and splenic involution, total numbers of thymocytes and 
splenocytes, mitogen responsiveness and NK cell activity 
15 mg/kg in drinking water to 22-month-old female C57BL mice for 60 
consecutive days 
[79] 
Aging-induced immunosuppression Increases humoral response (IgG1 and IgM levels) 
Subcutaneous injection of 10 mg/kg for 7 days to 28-month-old male Wistar 
rats 
[106] 
Aging-induced immunosuppression 
Increases total leukocyte and lymphocyte counts, mitogenic response of 
splenocytes and delayed type hypersensitivity response 
Daily subcutaneous administration of 0.25 mg/kg to squirrels [107] 
Aging-induced immunosuppression Increases B cell proliferation and Th1 cytokines and decreases Th2 response Injection of old (16.5 months) female C57BL/6 mice [108] 
Immunosenescence induced by aging plus 
ovariectomy 
Restores impaired chemotaxis, mitogenic response, IL-2 release and NK cell 
activity 
1 mg/kg in drinking water to Wistar albino female rats [87] 
Dexamethasone-induced immunosuppression 
Restores decreased thymus and spleen activities, lymphoid tissues mass,  
total leukocyte counts and bone marrow and T cell-mediated immune function 
25 mg/kg to adult squirrels along with dexamethasone  
for 60 consecutive days 
[80] 
Dexamethasone-induced immunosuppression 
Enhances IL-2 production and thymic and splenic lymphocyte proliferation by 
membrane receptor-mediated mechanism 
Daily subcutaneous administration of 0.25 mg/kg to squirrels during evening 
hours 
[59] 
Corticosterone-induced immunosuppression Antagonizes the depression of antibody production Evening injections to mice [109] 
Immunosuppression due to propranolol- and 
PCPA-induced pineal inactivation 
Reverses the suppression of the humoral response and autologous mixed 
lymphocyte reaction 
Evening injections to mice [109] 
Immunosuppression by trauma-hemorrhage 
Improves reduced IL-1, IL-2 and IL-6 release and splenocyte proliferative 
capacity 
Subcutaneous injection of 10 mg/kg in the evening of the day of surgery  
(soft-tissue trauma and hemorrhagic shock) and on the following evening in 
C3H/HeN mice 
[92] 
Lead-induced immunotoxicity 
Increases thymus weight and splenic T and B cell and NK, T and B cell 
functions 
10 or 50 mg/kg orally administered to ICR mice daily for 28 days,  
2 h before Pb treatment 
[110] 
PCPA: p-chlorophenylalanine; Pb: lead; Ref: reference.
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Table 3. In vivo effects of melatonin on inflammatory conditions.  
 Inflammatory condition Melatonin effects Molecular mechanism References 
R
a
t
 
Exercise-induced cardiac inflammatory injury Reduces TNF-α, IL-1β and IL-6 production  [111] 
Experimental colitis Counteracts the high production of TNF-α, IL-1 and NO Downregulation of NF-κB [112] 
Diabetes-associated low-grade inflammation Lowers TNF-α, IL-6 and CRP  [113] 
Experimental model of traumatic brain injury Reduces upregulation of IL-6, iNOS, SOCS-3 and oxidative stress Overcomes STAT-1 inactivation [114] 
Heatstroke-induced multiple organ dysfunction syndrome 
Attenuates high production of TNF-α, IL-1β and IL-6 and  
promotes IL-10 production 
 [94] 
Ischemia reperfusion-induced liver damage Attenuates enhanced levels of TNF-α, IL-6 and NO 
Suppresses the increase in MyD88, ERK, 
phosphorylated JNK and c-Jun and nuclear 
translocation of NF-κB 
[115] 
Neuroinflammation in experimental diabetic neuropathy Attenuates elevated levels of TNF-α, IL-6, iNOS, COX-2 and oxidative stress Decreases NF-κB cascade activation [116] 
FK506-induced nephropathy Lowers TNF-α, IL-6 and NO levels  [117] 
Acetic acid-induced colitis Reverses increased levels of TNF-α, IL-1β, IL-6, MPO and oxidative stress  [118] 
Cerulein-induced pancreatitis Reduces expression of TNF-α, IL-1β, IL-6, IL-8 and iNOS Inhibition of elevated nuclear binding of NF-κB [119] 
Hemorrhagic shock Suppresses the release of TNF-α and IL-6  [120] 
DMN-induced liver injury Decreases expression of TNF-α, IL-1β, IL-6 and iNOS Inhibition of increased nuclear binding of NF-κB [121] 
Aging Attenuates increased levels of TNF-α, IL-1β, IL-6, iNOS and LPO  [122] 
Cecal dissection-induced bacterial peritonitis Lowers levels of TNF-α, IL-6 and MDA  [123] 
Pancreatic fluid-induced lung inflammation and airway hyperreactivity Reduces TNF-α and iNOS concentrations  [95] 
TNBS-induced colitis Decreases high levels of TNF-α, IL-1 and NO NF-κB inhibition and blockade of IκBα degradation [112,124] 
Neuro-inflammation induced by intra-cerebroventricular  
administration of LPS 
Decreases TNF-α, IL-1β and oxidative stress  [125] 
Experimental periodontitis Reduces TNF-α, IL-1β and MDA  [126] 
DNBS-induced colon injury Reduces expression of TNF-α and MMP-9 and MMP-2 activities Reduction in NF-κB activation and phosphorylation  
of c-Jun 
[127,128] 
Taurocholate-induced acute pancreatitis Reduces TNF-α and amylase levels  [129]  
Escherichia coli-induced pyelonephritis Reverses increased levels of TNF-α and MDA  [130] 
Spinal cord injury Decreases expression of TNF-α and MMP-9 and MMP-2  [127] 
Lung ischemia-reperfusion injury Diminishes levels of TNF-α Inhibition of NF-κB protein levels [131] 
Hypoxia-induced retinal ganglion cell death Reverses the upregulation of TNF-α, IL-1β and LPO  [132] 
Mechlorethamine-induced nephrotoxicity Ameliorates the increased production of TNF-α and IL-1β  [133] 
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Table 3. Cont. 
 Inflammatory condition Melatonin effects Molecular mechanism References 
M
o
u
s
e
 
Immunological liver injury Attenuates the increases in TNF-α and IL-1β  [134] 
Radiation-induced lung injury Reduces TNF-α, TGF-1 and oxidative stress  [135] 
Maternal LPS-induced inflammation Attenuates elevation of TNF-α in maternal serum and fetal brain  [136] 
Indomethacin-induced chronic gastric ulcer Blocks expression of TNF-α, IL-1β and IL-8 Inhibition of ERK and JNK phosphorylation and 
NF-κB, c-Fos and c-Jun expression [137] 
Alzheimer’s transgenic mice Decreases TNF-α levels in hippocampus  [138] 
H
u
m
a
n
 
Infant endotracheal intubation Lowers IL-6, IL-8, IL-10 and IL-12  [139] 
Strenuous exercise Prevents overexpression of TNF-α, IL-6, IL-1ra and oxidative stress  [140] 
Duchenne muscular dystrophy Reduces levels of TNF-α, IL-1β, IL-6, IL-2, IFN-γ and oxidative stress  [141] 
Respiratory distress syndrome Limits serum rise in TNF-α, IL-6 and IL-8  [142] 
CRP: C-reactive protein; MPO: myeloperoxidase; NO: nitric oxide; DMN: dimethylnitrosamine; TNBS: 2,4,6-trinitrobenzenesulfonic acid; DNBS: dinitrobenzene sulfonic acid; empty spaces indicate unknown  
molecular mechanisms.  
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In vitro approaches have also highlighted the molecular mechanisms involved in the anti-inflammatory 
actions of melatonin. Melatonin inhibited LPS-stimulated TNF-α, IL-1β, IL-6, IL-8 and IL-10 production 
in Raw264.7 cells through a mechanism involving the attenuation of NF-κB activation [143]. 
Similarly, melatonin suppressed the production of LPS-activated IL-6 and NO in Prevotella intermedia 
by blocking NF-κB signaling through the inhibition of the nuclear translocation and DNA-binding 
activities of the NF-κB p50 subunit and suppression of STAT-1 signaling [144]. Additionally, 
melatonin decreased TLR3-mediated TNF-α and iNOS expression via inhibition of NF-κB activation 
in respiratory syncytial virus-infected Raw264.7 cells [145]. Melatonin also attenuated both the 
methamphetamine-induced upregulation of TNF-α, IL-1β and IL-6 in the HAPI rat microglial cell  
line [146] and the amyloid-beta-induced over-production of TNF-α and IL-6 in organotypic hippocampal 
cultures [147]. In conclusion, numerous studies have demonstrated that melatonin is an anti-TNF-α 
compound, which should be taken into account for future clinical trials. Similarly, a protective effect 
for melatonin in TNF-α-induced muscle atrophy in L6 myotubes was recently described [148]. 
3.2. Immunomodulatory Actions of Melatonin in the Specific Immune Response  
Broadly speaking, melatonin exerts positive effects on the cellular and humoral responses under 
basal or immunosuppressed conditions. As early as 1986, Maestroni et al. reported that reconstitution 
of the nighttime plasma melatonin peak completely abrogated the humoral and cellular responses in 
propranolol-immunosuppressed mice [109]. Mice immunosuppressed by lead recovered splenic  
CD4+ cell numbers and functions after melatonin treatment [110]. Melatonin also averted age-induced 
immunosuppression in rats by increasing IgG1 and IgM levels [106]. Furthermore, melatonin significantly 
restored both dexamethasone- and aging-induced immunosuppression in squirrels [59,80,107]. 
Melatonin also increased B cell proliferation and the Th1 response (IL-2 and IFN-γ production) and 
decreased Th2 cytokines such as IL-10 in old mice [108]. 
Early in vitro studies suggested that melatonin has pro-Th1 effects [75]. Sub-stimulated PBMCs 
displayed enhanced production of Th1 cytokines, such as IFN-γ and IL-2, after in vitro melatonin 
treatment [71,75]. The diurnal rhythmicity of human cytokine production indicated that the  
IFN-γ/IL-10 peak occurs during the early morning; this peak positively correlated with plasma 
melatonin [149], suggesting a melatonin/Th1 causality. Splenocyte proliferation in response to the T 
cell mitogen concanavalin A was also enhanced by the addition of melatonin in vitro [150].  
Conversely, melatonin significantly reduced the splenic CD19+ B-cell population in mice  
with experimental membranous nephropathy and diminished the overexpression of TNF-α, IL-1β and 
IFN-γ [151]. Further in vivo studies have shown the capacity of melatonin to promote a Th2 response 
in several models. The first report demonstrated that high doses of melatonin enhanced the production 
of the hallmark Th2 cytokine IL-4 in bone marrow lymphocytes [152]. Early nocturnal sleep induced  
a shift in the Th1/Th2 cytokine balance towards increased Th1 activity, whereas the Th2 response 
dominated during late sleep. A robust decrease in TNF-α-producing CD8+ cells was also observed 
during sleep [153], suggesting a correlation between melatonin and the Th2 response. Likewise, the 
absence of melatonin due to pinealectomy polarized rat thymic Th1/Th2 cells towards a Th1 response 
by increasing the production of IFN-γ and reducing IL-10 levels, implying that melatonin skews the 
immune response towards Th2 dominance [154]. Chronic administration of melatonin to antigen-primed 
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mice increased the production of IL-10 and decreased the secretion of TNF-α, suggesting a Th2 
response [155]. Melatonin inhibited the Th1 response by suppressing IFN-γ and IL-12 in mice with 
contact hypersensitivity [156]. Furthermore, melatonin protected against experimental reflux esophagitis by 
suppressing the Th1-mediated immune response [58]. Melatonin also acted as an immunosuppressive 
agent and reduced Th1 cytokine levels in an experimental model of ovarian transplant in mice, 
permitting prolonged graft survival [157].  
The modulation of cytokines by melatonin in several in vivo models also supports an anti-Th1 
response. Melatonin increased IL-10 production both locally and systemically in an experimental mouse 
model of septic shock [158]. Melatonin also significantly reversed both aging- and ovariectomy-induced 
reductions in IL-10 levels in rats [122]. Moreover, melatonin suppressed the development of 
experimental atopic dermatitis in NC/Nga mice by reducing total IgE, IL-4 and IFN-γ levels released 
from activated CD4+ cells [159]. It was found that the stimulation of IL-10 production is one 
mechanism by which melatonin exerts beneficial effects in acute pancreatitis [96]. Suppressed 
melatonin synthesis due to light exposure in mice increased IgM, IgG2a, IgG2b and IgG3 antibody 
levels after immunization with T cell-dependent antigens, while IgG1 antibody levels were 
significantly decreased [160]. Because IgG2a and IgG1 are typical hallmarks of the Th1 and Th2 
responses, respectively, these results might support the idea of a Th1-biased effect with a melatonin 
deficit. Although there are no reports that have explored Th17 cells in relation to melatonin, we 
recently identified the Th17 lineage-specific transcription factor RORα as a natural target of melatonin 
in T cells [69]. RORα, along with RORγ, regulates Th17 cell differentiation [161], whereas the  
downregulation of RORα expression has been shown to be part of the typical Treg transcriptional 
signature [162]. A preliminary study highlighted the in vivo inhibitory actions of melatonin on Treg 
cell generation in cancer patients [163]. Additionally, the in vivo administration of melatonin to mice 
subjected to experimental cancer via inoculation of a foregastric carcinoma cell line was associated 
with the downregulation of CD4+CD25+ Treg cells and Foxp3 expression in the tumor tissue [164].  
4. Clinical Relevance of Melatonin  
4.1. Melatonin and Infection 
In recent decades, melatonin has been reported to possess important functions as an antiviral, 
antibiotic and anti-parasitic molecule [165,166] (Scheme 1). In addition, a substantial body of research 
has highlighted the increased survival of animals subjected to septic shock after the administration of 
melatonin. The beneficial effects of melatonin manifest through its pleiotropic properties as an 
immunomodulator [18], antioxidant [167] and cyto-protector [158].  
4.1.1. The Role of Melatonin in Viral Infections  
Increasing doses of melatonin (0.25 to 1 mg/kg) administered to mice infected with Venezuelan 
equine encephalomyelitis virus (VEEV) were found to reduce mortality up to 16% compared to 100% 
mortality in non-melatonin-treated mice [168]. Melatonin reduced viral levels in the brains of 
immunocompetent mice but not in immunosuppressed mice, suggesting that melatonin requires the 
integrity of the immune system for antiviral activity [169]. Additionally, melatonin significantly 
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increased serum levels of TNF-α, IL-1β and IFN-γ. Blockage of IL-1β with anti-murine IL-1β 
antibodies completely neutralized the protective role of melatonin, suggesting that IL-1β is the main 
target for the rapid viral clearance induced by melatonin [170]. Melatonin also increased IL-1β levels 
in the brains of infected animals; in contrast, indoleamine reduced the production of TNF-α, 
contributing to the localized control of the inflammatory response in the brain [171]. In addition to 
modulating cytokine production, melatonin treatment diminished high nitrite concentrations and 
reduced the amounts of lipid peroxidation products in the brains and sera of infected mice [172]. 
Scheme 1. Melatonin in immune intervention. 
 
Administration of melatonin prevented paralysis and death in mice infected with sub-lethal  
doses of encephalomyocarditis virus (EMCV) after acute stress [173]. Melatonin also reduced 
mortality due to persistent parvoviral infection (Aleutian disease) in mink, which results in marked 
hypergammaglobulinemia and immune complex-mediated tissular lesions [174]. The antiviral activity 
of melatonin was also evaluated in normal mice inoculated with Semliki Forest virus (SFV) and in 
stressed mice injected with attenuated non-invasive West Nile virus (WN-25). Administration of daily 
melatonin starting three days before virus inoculation and continuing 10 days after inoculation reduced 
viremia, significantly reduced mortality, and postponed the onset of disease and death [175]. 
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The experimental murine acquired immune-deficiency syndrome (AIDS) induced by LP-BM5 
leukemia retrovirus induces inhibition of Th1 cytokine release, stimulates Th2 cytokine  
secretion, enhances hepatic lipid peroxidation and causes vitamin E deficiency. Administration of 
dehydroepiandrosterone (DHEA) and/or melatonin prevented the reduction of B and T cell proliferation 
and Th1 cytokine secretion in female C57BL/6 mice with AIDS [176]. In terms of AIDS caused by 
human immunodeficiency virus type I (HIV-1), a positive correlation between serum levels of 
melatonin and IL-12 has been demonstrated. Additionally, a negative correlation between melatonin 
and plasma HIV-1 RNA levels has been observed; supporting this negative correlation, levels of serum 
melatonin in HIV-1-infected individuals were found to be significantly lower than in healthy  
controls [177].  
4.1.2. The Role of Melatonin in Bacterial Infections  
The protective actions of melatonin against bacterial infections have been evaluated for the cultured 
H37Rv strain of Mycobacterium tuberculosis (M. tuberculosis). Melatonin supplied at a concentration 
of 0.01 mM, together with isoniazid, a frontline drug used in the treatment of tuberculosis, inhibited 
bacterial growth three to fourfold more than either of these compounds alone [178]. When intracellular 
bacterial growth was examined in infected monocytes, the addition of either isoniazid or melatonin 
alone did not have any effect on macrophage mortality or viability. However, their combination 
resulted in a marked reduction in bacterial loading. The microbicidal action of melatonin might be 
attributed to its capacity to form stable radicals that could either modify isoniazid action or bind to the 
mycobacterial cell wall, resulting in destabilization of the cell wall and causing enhanced permeability 
to isoniazid molecules. Mean plasma melatonin and aMT6 levels are lower in patients infected by  
M. tuberculosis than in control subjects [179]. Some studies have also shown that peaks in  
M. tuberculosis infection coincide with both the end of winter and the beginning of the summer  
season [180,181], suggesting that seasonal changes in the immune system caused by annual 
fluctuations in melatonin levels could be involved [179,182]. The microbicidal activity of melatonin 
has also been evaluated in chlamydial infections. The major defense mechanism against chlamydial 
infection is the synthesis of IFN-γ by the host and the subsequent induction of indoleamine  
2,3-dioxygenase, resulting in the depletion of tryptophan from human cells [183]. Therefore, a deficit 
in melatonin production promoted by tryptophan depletion would be expected in chlamydial 
infections. In vitro administration of melatonin to three Chlamydiaceae species, Chlamydia trachomatis, 
Chlamydophila pneumoniae and Chlamydophila felis, reduced infection by 50%. This reduction was 
neutralized by pertussis toxin, an inhibitor of G proteins [184], which suggests a membrane  
receptor-mediated mechanism. An additional study demonstrated the in vitro anti-microbial  
activity of melatonin against multidrug-resistant Gram-positive and Gram-negative bacteria,  
methicillin-resistant Staphylococcus aureus, carbapenem-resistant Pseudomonas aeruginosa and  
Acinetobacter baumannii [185]. These results have clinical importance, as these strains have recently 
emerged as primary nosocomial pathogens in hospital outbreaks. 
Sepsis encompasses a heterogeneous group of syndromes characterized by impaired body 
temperature, hypotension, vascular and myocardial dysfunction, hypoperfusion associated with cellular 
damage and, in severe cases, multiple organ failure [186]. It is a systemic response to the release of 
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bacterial endotoxins, mainly LPS, that activates polymorphonuclear cells (PMN), monocytes and 
lymphocytes. The release of cytokines, especially TNF-α, IL-1β, IL-6, IL-12 and IFN-γ, and the 
generation of free radicals by PMNs and infiltrated macrophages in the tissues can lead to 
microvascular dysfunction and organ failure [186]; TNF-α and NO are essential mediators in the 
pathogenesis of sepsis and associated complications [187]. 
Several studies using experimental models of endotoxin-induced sepsis and multibacterial sepsis 
have demonstrated the important protective role of exogenous melatonin [158,187–192]. Supporting 
these studies, exposure to short photoperiods with the subsequent increase in endogenous melatonin 
was found to augment the survival of septic Siberian hamsters and to diminish TNF-α levels compared 
to animals exposed to long photoperiods [193]. 
The mechanisms of melatonin action in sepsis reflect the pleiotropic capacity of the molecule. 
Melatonin blocks the overproduction of pro-inflammatory cytokines, especially TNF-α [158,190,194–196], 
and increases IL-10 levels [158,192,196]. In addition, melatonin was found to increase the weight  
of the spleen in endotoxin-septic rats compared with control animals [191] and to counteract  
sepsis-induced apoptosis in the spleen [158]. Moreover, melatonin neutralised inflammatory 
infiltration in different tissues of septic animals [197,198].  
The beneficial effects of melatonin are not confined to direct modulation of the immune system. 
Indeed, melatonin increases total antioxidant capacity [194] and/or reduces the production of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) and their deleterious effects on 
biomolecules in septic rodents [194,199,200]. Melatonin also protects against sepsis-induced damage 
of the mitochondria by restoring impaired mitochondrial antioxidant systems, enhancing both 
glutathione (GSH) levels and glutathione reductase (GRd) activity, inhibiting nitrite formation and 
inducing mitochondrial iNOS expression. Additionally, melatonin reduces mitochondrial lipid 
peroxidation in different tissues and decreases sepsis-induced alterations in mitochondrial respiratory 
chain activity and ATP synthesis [187,201]. 
As with most inflammatory conditions that have been tested, the intracellular actions of melatonin 
in experimental models of sepsis involve the reduction of NF-κB nuclear translocation [196,202]. 
Melatonin also reduces p38 MAPK and poly ADP ribose synthase (PARS) activation, which is 
activated by DNA damage caused by ROS and RNS [202,203]. The effects of melatonin can be, at 
least in part, mediated by binding to the membrane receptors MT1 or MT2, as luzindole blocks 
melatonin-induced decreases in pro-inflammatory cytokines [190]. 
In humans, septic patients hospitalized in intensive care units (ICUs) were found to have altered 
circadian rhythms for 6-sulfatoxymelatonin (aMT6) urine excretion, with loss of circadian periodicity, 
diminished phase amplitude and delayed acrophase [204], but light exposure in the ICU was not 
responsible for this impairment in urine aMT6 excretion [205]. Additionally, nocturnal plasmatic 
melatonin levels were found to inversely correlate with illness severity in ICU patients with severe 
sepsis [206]. In a similar study performed in pediatric patients, nocturnal melatonin concentrations in 
children with sepsis in a septic shock state were significantly higher than those of septic patients not in 
a septic shock state. However, there was no significant difference in nocturnal aMT6 excretion 
between septic patients, with or without septic shock, and non-septic patients. Interestingly, 24-h 
aMT6 excretion in septic patients with liver dysfunction was significantly lower than in septic patients 
without liver dysfunction. Additionally, nocturnal melatonin concentrations in non-survivors were 
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significantly higher than in survivors, whereas total aMT6 excretion in non-survivors was significantly 
lower than in survivors [207,208]. The parallel measurement of serum melatonin together with the 
urine levels of aMT6 would provide convenient data to allow disturbances in aMT6 due to hepatic 
dysfunction to be discarded. Exogenous melatonin has also been shown to improve clinical outcome 
for septic newborns by reducing lipid peroxidation, white cell counts, neutrophil counts and  
C-reactive protein levels [209]. Moreover, melatonin reduces pro-inflammatory cytokine production 
(IL-6, IL-8, TNF-α), lipid peroxidation and nitrite and nitrate levels in newborns suffering from 
respiratory distress syndrome [142]. 
4.1.3. The Role of Melatonin in Parasite Infections  
Some studies have shown that TNF-α, IFN-γ and IL-12 are important for the control of 
Trypanosoma cruzi (T. cruzi) infection by ensuring the induction of an efficient adaptive host  
response [210]. Therefore, several reports have examined the effects of melatonin combined with other 
drugs in the control of experimental models of T. cruzi infection. Combined treatment with melatonin 
and meloxicam was found to reduce the levels of parasitemia and increase TNF-α, IFN-γ and IL-2 
production [211]. In conjunction with DHEA, melatonin diminished the parasite load in blood and 
tissue [212]. Despite a strong and vigorous anti-parasite immune response, melatonin was not able to 
completely clear infection, enabling T. cruzi to persist in a majority of hosts [213]. After T. cruzi 
infection, the thymus, a central lymphoid organ able to generate mature T cells, undergoes a dramatic 
loss in size, resulting in a reduction in the number of thymocytes. A recent study found that zinc 
combined with melatonin therapy triggered thymocyte proliferation in rats inoculated with T. cruzi 
compared to untreated animals [214]. 
Many studies have demonstrated that Plasmodium falciparum (P. falciparum), a parasite that 
colonizes hepatocytes and red blood cells (RBCs) and causes the deadly disease malaria, depends on 
intracellular calcium. Authors have stated that melatonin and its precursors derived from the 
tryptophan catabolism induce calcium release and modulate the P. falciparum cell cycle [215].  
4.2. Melatonin and Autoimmunity: A Winding Road 
Some studies have implicated both endogenous and exogenous melatonin in the development of 
different autoimmune diseases (Scheme 1), including rheumatoid arthritis (RA), multiple sclerosis 
(MS), systemic lupus erythematosus (SLE), type 1 diabetes (T1D) and inflammatory bowel disease 
(IBD). However, results describing the relationships between melatonin and other autoimmune 
diseases are scarce. One study found a loss of nocturnal melatonin elevation and increased morning 
plasmatic melatonin levels in psoriasis patients [216]. Furthermore, melatonin reduced type II 
collagen-induced proliferation of lymphocytes in patients with autoimmune hearing loss [217] and 
protected against autoimmune glomerulonephritis in an experimental model of idiopathic membranous 
nephropathy [151]. 
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4.2.1. Melatonin and Rheumatoid Arthritis 
The effects of melatonin on RA, a common autoimmune disease suffered by approximately 1% of 
the world’s population [218], is controversial. Different studies using experimental models of arthritis 
have suggested deleterious actions for both endogenous and exogenous melatonin. Animals maintained 
in constant darkness undergo more severe collagen-induced arthritis and exhibit higher titers of serum 
anti-collagen antibodies than those kept under constant light or a normal photoperiod [219]. The 
effects of constant darkness were reversed by pinealectomy [220]. Furthermore, administration of 
melatonin to mice immunized with rat collagen II and kept under constant light promoted more severe 
arthritis when it was injected at the beginning of the immunization, whereas melatonin injection at the 
onset of the disease (day 30–39) did not affect the clinical signs of the disease [221]. An additional 
study showed that melatonin increased serum anti-collagen antibody titers and IL-1β and IL-6 levels in 
the serum and joints of arthritic rats, while it decreased oxidative markers in serum but not in joints. As 
expected, pinealectomy had an opposite effect compared to melatonin, resulting in reduced antibodies, 
cytokine levels and oxidative stress in joints but also elevated oxidative markers in serum [222]. In 
contrast with those studies supporting the deleterious effects of melatonin, prophylactic and/or 
therapeutic treatment with melatonin reduced hind paw swelling similar to indomethacin in an 
adjuvant-induced arthritis model [223]. 
An increase in the incidence and severity of RA has been shown to be associated with higher 
latitudes, suggesting that augmented melatonin production during long winter nights could be related 
to RA. Supporting this notion, the nocturnal levels of melatonin in RA patients from Estonia were 
found to be higher than those in Italian patients [224]. Moreover, the risk of arthritis is inversely 
associated with UV-B exposition [225], which is radiation known to reduce pineal synthesis of 
melatonin [226]. RA symptoms are also worse in the early morning [224], coinciding with high levels 
of pro-inflammatory cytokines and low serum concentrations of cortisol [227]. Interestingly, some 
authors have reported a rise in serum melatonin levels during the early morning in RA patients 
compared with healthy controls, a positive correlation between melatonin levels and disease activity 
scores and an advance in the nocturnal melatonin peak compared to control subjects [228–230]. 
However, other authors have reported significantly lower levels of morning plasmatic melatonin [231] 
and increased nocturnal pineal production of melatonin induced by Freund’s adjuvant in an 
experimental model of arthritis [232].  
In vitro, cultured RA synovial macrophages have high-affinity binding sites for melatonin [233] and 
produce high levels of IL-12 and NO after melatonin administration [234]. Additionally, synovial fluid 
from RA patients has relatively high levels of melatonin [233]. Conversely, melatonin inhibits the 
excessive proliferation of RA fibroblast-like synoviocytes through activation of the cyclin-dependent 
kinase inhibitors P21 (CIP1) and P27 (KIP1) mediated by ERK [235]. Fibroblasts from synovial 
membranes collected from RA patients also show impaired circadian expression of timekeeping genes 
and pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 [236]. 
Interestingly, the only study conducted in RA patients with active disease receiving daily melatonin 
at night over six months reported low antioxidant profiles in patients, increased neopterin concentrations 
and erythrocyte sedimentation rates (inflammation indicators) and no changes in pro-inflammatory 
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cytokine levels (TNF-α, IL-1β and IL-6), but these effects were not associated with any changes in 
clinical symptoms [237]. 
4.2.2. Melatonin and Multiple Sclerosis 
Multiple sclerosis (MS), a progressive neurodegenerative disorder triggered by an autoimmune 
response against myelin [238], is the most common neurological disease in young adults, with a 
worldwide prevalence of 1.1–2.5 million cases [239]. Although the etiology of MS is not currently 
fully understood, one environmental factor that appears to be implicated is latitude, as the prevalence 
of the disease increases in northern countries [240]. This might be associated with a reduction in 
daylight exposure [241,242], as a diminished prevalence of MS has been described in mountainous 
areas with respect to neighboring lower areas [243]. Recently, shiftwork at a young age has been 
associated with increased incidence of MS, with a positive correlation between the risk of MS and the 
duration of shift work [244]. 
MS patients exhibit impaired circadian rhythms for both melatonin and aMT6. A high percentage of 
patients with exacerbated MS were shown to display an inverted melatonin circadian rhythm [245] and 
alterations in aMT6 urine excretion, specifically lower total urine aMT6 levels than healthy controls. 
Additionally, patients exhibited significantly reduced night-time excretion of aMT6 when compared 
with controls, normalized by IFN-β treatment [246]. In addition to studies of melatonin action over the 
course of the disease, endogenous melatonin has been related to the clinical complications of MS. 
Serum melatonin levels inversely correlate with depression in MS patients [247]. Additionally, diurnal 
vision impairment related to MS was shown to be linked to the melatonin circadian rhythm; more 
importantly, it was improved by oral treatment with melatonin [248]. 
Although some epidemiological studies might indirectly suggest a detrimental effect for melatonin 
in MS, studies using an experimental autoimmune encephalomyelitis (EAE) model have reported 
contradictory results. Luzindole administration suppressed EAE [249] and pinealectomy showed an 
age-dependent effect on EAE; when new-born rats were pinealectomyzed, they suffered extensive 
pathological damage and severe neurological deficits after EAE induction, but adult pinealectomyzed 
rats were protected against the development of EAE [250]. Moreover, exogenous melatonin reduced 
both the severity and the duration of EAE-induced paralysis in rats and diminished both macrophage 
and CD4+ and CD8+ T cell infiltration in the spinal cord and ICAM-1 expression in the blood vessels 
close to EAE lesions [251]. 
4.2.3. Melatonin and Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder with a yearly 
incidence of 1 to 10 and an estimated prevalence of approximately 20–150 cases per 100,000 people. 
A hallmark of SLE is the formation of immune complexes in blood and tissues that cause extensive 
tissular damage. The sustained immune response causes lupus patients to develop localized inflammatory 
episodes that give rise to a vicious circle in which the autoimmune response leads to a number of 
immunological abnormalities and tissue destruction [252].  
An uncoupled melatonin circadian rhythm has been described in lupus-prone mice [253]. However, 
melatonin levels and seasonal light variations show no association with disease activity in SLE patients 
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from a subarctic region [254]. Melatonin administration exerts contradictory effects in experimental 
models of SLE; it has been shown to be beneficial or deleterious depending on parameters such as 
timing of the administration and gender. Melatonin administered in the morning increased the survival 
of lupus-prone animals, although the effect was not reproduced after evening treatment [255]. 
Additionally, melatonin reduced vascular lesions and inflammatory infiltration in the kidneys, 
diminished titers of anti-collagen II and anti-dsDNA autoantibodies, reduced the production of  
pro-inflammatory cytokines and increased the release of anti-inflammatory cytokines in both female 
lupus-prone animals [256] and pristane-induced lupus [257]. However, melatonin had no effect or 
actually worsened the disease in male lupus-prone mice [256]. 
4.2.4. Melatonin and Type 1 Diabetes 
Type 1 diabetes (T1D) is an autoimmune disease in which the immune response against pancreatic 
β-cells causes an insulin deficit. Although T1D only accounts for 5%–10% of all cases of diabetes, its 
incidence is rising worldwide [258]. As for most autoimmune pathologies, a latitudinal gradient of 
T1D incidence has been demonstrated, with cases increasing with latitude. It has been proposed that 
this relationship is associated with UV exposure and vitamin D levels [259], although melatonin 
involvement cannot be ruled out. Interestingly, low levels of insulin in experimental models of T1D 
correlate with increased production of melatonin, which is normalized by insulin administration [260]. 
Pinealectomy of newborn non-obese diabetic (NOD) mice, a mouse model of autoimmune T1D, was 
shown to significantly diminish survival and induce glycosuria, whereas chronic administration of 
melatonin increased survival and delayed the onset of the disease, facilitating the maintenance of 
normal plasmatic glucose levels [261]. Moreover, melatonin reduced the proliferation of splenocytes 
and Th1 cells, prolonging the survival of pancreatic islet grafts in NOD mice [262]. Melatonin is not 
only useful for preventing the development of T1D but also shows protective effects against  
diabetes-associated cardiovascular disturbances by improving vascular contractile performance in 
diabetic rats [263] and reducing blood pressure in T1D teenagers [264].  
4.2.5. Melatonin and Irritable Bowel Syndrome/Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) encompasses a group of inflammatory diseases that includes 
ulcerative colitis and Crohn’s disease; for these two diseases, both the innate and adaptive immune 
responses appear to be implicated [265]. Irritable bowel syndrome (IBS) is a functional gastrointestinal 
disorder associated with visceral hypersensitivity and abnormal gastrointestinal motor functions [266]. 
A relationship between impaired melatonin synthesis and secretion and IBS has been suggested, as 
urinary levels of aMT6 are lower in IBS patients than in healthy controls. In support of this, altered 
melatonin levels have been shown to be important for the disease, and some clinical trials have 
demonstrated the beneficial effects of the agent in reducing abdominal pain [267,268] and  
distension [267] and improving rectal sensibility [268], IBS scores and quality of life [269,270]. 
The impairment of circadian rhythmicity has also been shown to be related to the course of IBD  
in experimental models. Mice subjected to continuous changes of the light/dark cycle or to sleep 
deprivation have been shown to exhibit more severe colitis with increased weight loss and mortality 
compared to control animals [271,272]. Furthermore, melatonin promoted beneficial effects in  
Int. J. Mol. Sci. 2013, 14 8658 
 
 
several experimental models of colitis in rodents. It reduced visceral hyperalgia [273] and diminished 
disease severity [274,275] by antioxidant mechanisms, reducing lipid peroxidation and nitrosative  
stress [275,276] and protecting endogenous antioxidants from depletion [118]. Moreover, melatonin 
was shown to modulate the immune attack on the colonic mucosa by regulating the activities of 
macrophages [277] and matrix metalloproteinases (MMP) 2 and 9 [127] and by suppressing iNOS and 
COX-2 activities [276], pro-inflammatory cytokine levels [118,128] and adhesion molecules [124]. 
Furthermore, melatonin has been shown to modulate apoptosis in colitis models [128]. Intracellular 
actions such as NF-κB inhibition and c-Jun activation have also been associated with the effects of 
melatonin on colitis [124,128].  
Although available data regarding melatonin treatment in experimental models of colitis suggest 
positive effects, to date, no clinical trials have been conducted to investigate the effects of melatonin 
on IBD. Only three case reports have been published, each with different results. While a patient 
suffering ulcerative colitis observed that melatonin caused the disappearance of clinical symptoms and 
that these symptoms reappeared when melatonin consumption stopped [278], the other two cases, one 
an ulcerative colitis patient and the other a patient with Crohn’s disease, experienced an exacerbation 
of their respective diseases, which remitted after melatonin intake ceased [279,280]. 
4.3. Melatonin and Vaccination: A Worthwhile Area to Explore  
Vaccines have been successfully used to establish or improve immunity to a particular disease. The 
immunity-promoting activity of a vaccine is not only determined by the particular antigenic component 
utilized but also by the addition of suitable adjuvants that are capable of activating and promoting an 
efficient immune response against the infectious agent of interest. Based on the immunoregulatory 
properties of melatonin, some in vivo studies have explored its use in vaccination (Scheme 1). 
Melatonin was shown to increase the humoral responses of sheep vaccinated against Dichelobacter 
nodosus [281], which is the bacteria that causes ovine footrot, a major cause of lameness in  
sheep [282]. In this study, the administration of subcutaneous slow-release melatonin implants  
(18 mg/animal given 21 days after the first dose of vaccine) increased antibody titers in synergy with 
aluminum hydroxide. Double doses of melatonin notably increased antibody titers and IgG levels 
compared to untreated, vaccinated animals [283]. The administration of melatonin either via implants 
or injections also enhanced the platelet response to thrombin stimulation, improving the percentage 
and rate of aggregation and lag-time [284]. The beneficial effects of melatonin on the immune 
response to vaccination against Clostridium perfringens type D in sheep have also been  
described [285]. Interestingly, the highest increases in serum antibody levels due to melatonin were 
observed when vaccination took place prepartum, suggesting that the time of immunization plays an 
important role in determining the effects of melatonin on the immune response. The powerful immune 
response originating after the administration of melatonin via implants might be explained through two 
primary mechanisms: melatonin could effectively augment the antibody response by enhancing antigen 
presentation to immunocompetent cells [18,89], or melatonin could modulate cytokine production at 
the beginning of the immune response and could therefore control important cellular responses. The 
potential role of melatonin as an adjuvant has also been suggested in studies examining vaccines 
developed against prostate cancer [286].  
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The goal of an immunization program should not only be restricted to protection against infection 
but should also include modulation of the pathology inflicted by the agent. To evaluate this, the 
administration of melatonin in combination with different immunization regimens using various 
Schistosoma mansoni antigens in hamsters (with schistosomiasis) was evaluated [287]. Melatonin 
provided excellent enhancement of vaccine action with cercarial and soluble worm antigens; this was 
accompanied by significant improvements in GSH levels. Taking into account its antioxidant  
capacity [288], melatonin protected against inflammation associated with Aβ vaccination via direct 
and indirect actions [289], suggesting that it could also be an effective adjuvant in vaccines developed 
for immunotherapy of Alzheimer’s disease (AD). Immune cell functions are strongly influenced by the 
antioxidant/oxidant balance; thus, antioxidant levels in these cells play a pivotal role in protecting 
against oxidative stress and preserving adequate cellular function. The immunoregulatory and 
antioxidant properties of melatonin were also demonstrated in an open-field vaccination procedure in 
sheep against D. nodosus [290]. In this study, the co-administration of melatonin with footrot vaccine 
neutralized the rise of serum NO found in vaccinated animals. This effect could be explained by the 
direct action of melatonin on NO or by its known inhibitory actions against iNOS activity.  
4.4. Immunological Aspects of Melatonin in Transplantation 
All experimental studies performed in models of perfused organ transplantation have shown  
the beneficial effects of melatonin in prolonging graft survival (Scheme 1). Indeed, treatment with high 
doses of melatonin (200 mg/kg/bw) were shown to inhibit the immune response to allografts by 
reducing the proliferation capacity of lymphocytes, preventing rejection and doubling allograft 
survival in a rat cardiac transplant model [291]. Similar protective effects were observed in rat lungs 
following reperfusion injury after prolonged ischemia [292]. High doses of melatonin reduced the 
proportion of Th1 cells and elevated the percentage of IL-10-producing cells, significantly prolonging 
pancreatic islet graft survival in NOD mice [262]. The immunosuppressive effects of melatonin 
supplementation were also evident in a model of autologous intraperitoneal ovary transplantation in 
rats. A single application of melatonin attenuated ovarian tissue necrosis following engraftment [293]. 
In line with this finding, a more recent study reported a reduction of apoptosis in human ovarian grafts 
in melatonin-treated hosts [294]. The reductions in both apoptosis [294] and necrosis [293] might be 
related to the anti-apoptotic and antioxidant properties of melatonin. Another potential mechanism by 
which melatonin can exert beneficial effects following transplantation is the inhibition of cellular 
damage caused by surgical stress and ischemia-reperfusion injury (IRI). This has been demonstrated in 
animal models of hepatic IRI in which melatonin supplementation exerted a protective effect  
in the liver [295]. Specifically, melatonin reduced neutrophil recruitment, increased GSH and 
decreased oxidative stress. Furthermore, the number of apoptotic cells was reduced after melatonin 
administration [296]. Therefore, melatonin might reduce graft immunogenicity following transplantation, 
directly improving clinical outcome.  
The usefulness of melatonin as an additive for increasing the quality of organ preservation solution 
has also described. In a recent study, the addition of melatonin to Institute Georges Lopez (IGL-1) 
solution improved non-steatotic and steatotic liver graft preservation, limiting their risk for cold  
IRI [297]. The benefits of melatonin correlated with the generation of NO and the prevention of 
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oxidative stress and inflammatory cytokine release, including TNF-α and adiponectin. Recently, 
melatonin was used in multidrug donor preconditioning (MDDP), which improved liver preservation 
and completely prevented hepatic reperfusion injury [298,299]. This MDDP protection was provided 
by the antioxidative, anti-inflammatory and anti-apoptotic actions of melatonin. The immunosuppressive 
potential of melatonin is also evident, as immunosuppressive maintenance therapy with cyclosporine A 
was shown to increase midnight melatonin levels [300]. 
4.5. Melatonin and Immunosenescence 
Aging reflects the sum of the progressive changes that occur in several key physiological systems, 
including the immune system, which is continuously remodeled over the course of life, a process 
known as immunosenescence. Many age-related pathophysiological conditions, such as increased 
susceptibility to infectious diseases, neoplasias, metabolic diseases, osteoporosis and autoimmune 
diseases, are directly associated with immunosenescence [301]. It is interesting to note that many 
hormones that are associated with the maintenance of immune function also decline with advancing 
age and that the relationship between the endocrine system and the immune system is considered to be 
of crucial importance in normal human physiology and in mediating age-associated degenerative 
diseases [302,303]. The decline in the production of a number of hormones associated with aging, such 
as melatonin, has been proposed to play a significant role in contributing to immunosenescence [302]. 
With some exceptions [304,305], the age-associated decline of melatonin has been repeatedly  
reported [306–311] and usually overlaps with age-related impairment of the immune system.  
Although there are many studies that have demonstrated the immunomodulatory properties of 
melatonin, there have been only a limited number of investigations related to immunosenescence 
(Scheme 1). The administration of melatonin in normal or immunocompromised mice was shown to 
result in elevated antibody responses in vitro and in vivo [312]. Significantly, loss of thymocytes with 
age is the main cause of structural thymic atrophy and thymic weight loss. However, melatonin 
administration rejuvenated degenerated thymuses and corrected peripheral immune dysfunctions in 
aged mice [79]. This reversal of age-related thymic involution by melatonin could be attributable to 
increased thymic cellularity due to its anti-apoptotic and proliferation-enhancing effects [313]. The 
antioxidant activity of melatonin and its metabolites may also account for its anti-apoptotic effects on 
immune cells [314,315]. In fact, melatonin is able to delay endoplasmic reticulum stress-induced 
apoptosis in aged leukocytes and may counteract age-related degenerative phenomena linked to 
oxidative stress at the cellular level [316]. It was shown that age-related increases in oxidative burden 
were reversed by melatonin in golden hamsters, improving general immune status [317]. In another 
study, injections of melatonin restored immune functions in experimentally immunosuppressed or 
aging mice. Here, melatonin was able to enhance the antibody response to a T-dependent antigen. 
Moreover, the enhanced antibody response was associated with an increased induction of T helper cell 
activity and IL-2 production [318]. 
Additionally, melatonin has been demonstrated to exert inhibitory effects on various parameters of 
immune function. Melatonin has been shown to inhibit the production of pro-inflammatory cytokines, 
suggesting that indoleamine may help to reduce acute and chronic inflammation. Indeed, melatonin 
was able to reduce inflammation in the livers of senescence-accelerated prone (SAMP8) mice by 
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decreasing the mRNA and protein expression levels of TNF-α and IL-1β and increasing the IL-10 
expression level [319]. Similar data were also obtained with 24-month-old rats in which melatonin 
significantly reduced the levels of the pro-inflammatory cytokines TNF-α, IL-1β and IL-6 in the  
liver [122]. The immunomodulatory effects of melatonin in aging are also evident in the central 
nervous system (CNS), as dietary melatonin was shown to selectively reverse the lack of response to 
an inflammatory stimulus in the brains of aged mice [320].  
Based on the experimental data that have been accumulated and considering its lack of  
toxicity [321], high lipophilicity and great capacity to prevent cell damage [167], melatonin is one of 
the most attractive agents that has been investigated in relation to age-associated deterioration of the 
immune system and should be considered as a potential agent to improve quality of life in a rapidly 
aging population.  
5. Conclusions  
Currently, the role of melatonin as an effector that can modulate the immune system is undeniable. 
The almost ubiquitous distribution of melatonin receptors and its synthesis by the immune system 
underpin the melatonin/immune system relationship. The effects of several immunological mediators 
on melatonin production close the bidirectional circuit. 
In this review, we have highlighted the fact that melatonin acts on both the innate and specific 
responses of the immune system via combined mechanisms that mainly involve the modulation of 
cytokines and the production of oxidative stress. Overall, melatonin might act as an immunostimulant 
under basal or immunosuppressed conditions, providing a pre-activated state for a more effective early 
immune response against external stressors, such as viruses and parasites. However, in the presence of 
a transient or chronic exacerbated immune response, such as septic shock, melatonin might exert 
negative regulation and could be considered an anti-inflammatory molecule. Therefore, we have 
coined the termed “immunological buffer” in an attempt to define the pleiotropic, varied and complex 
effects of melatonin on the immune system in the most accurate way (Scheme 2). 
Scheme 2. Comprehensive graphic scheme depicting how melatonin buffers the immune system. 
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The various immunomodulatory actions exerted by melatonin have been successfully elucidated in 
several in vivo experimental models of inflammation, infection, sepsis or immunosenescence, and there 
has been general agreement that melatonin can be applied with negligible side effects. These 
conclusions, along with the future implementation of working models, such as melatonin knockout 
animals or highly specific monoclonal antibodies, will allow us to properly determine the scope of the 
pathophysiological role of melatonin to initiate more ambitious clinical trials. However, this will only 
be successful with firm commitment from both clinical researchers and companies to facilitate the 
progress of melatonin research from the bench to the patient bed.  
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